These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35527571)

  • 1. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
    McFarthing K; Rafaloff G; Baptista MAS; Wyse RK; Stott SRW
    J Parkinsons Dis; 2021; 11(3):891-903. PubMed ID: 34151864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of basket trials in drug development for neurodegenerative disorders.
    Cummings J; Montes A; Kamboj S; Cacho JF
    Alzheimers Res Ther; 2022 May; 14(1):73. PubMed ID: 35614479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.
    Abdelnour C; Gonzalez MC; Gibson LL; Poston KL; Ballard CG; Cummings JL; Aarsland D
    Neurol Ther; 2023 Jun; 12(3):727-749. PubMed ID: 37017910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Evans JR; Barker RA
    Expert Opin Pharmacother; 2011 Jun; 12(8):1249-58. PubMed ID: 21345151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study.
    Carroll CB; Webb D; Stevens KN; Vickery J; Eyre V; Ball S; Wyse R; Webber M; Foggo A; Zajicek J; Whone A; Creanor S
    BMJ Open; 2019 Oct; 9(10):e029740. PubMed ID: 31594876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials.
    Rees K; Stowe R; Patel S; Ives N; Breen K; Ben-Shlomo Y; Clarke CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008535. PubMed ID: 22071852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hopes for disease modification in Parkinson's Disease.
    Poewe W; Seppi K; Marini K; Mahlknecht P
    Neuropharmacology; 2020 Jul; 171():108085. PubMed ID: 32298705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.
    McGhee DJ; Ritchie CW; Zajicek JP; Counsell CE
    BMC Neurol; 2016 Jun; 16():92. PubMed ID: 27312378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.